TriangleNT-I7 for multiple myeloma (NCT07200089)
NT-I7 for multiple myeloma trial for Multiple Myeloma (NCT07200089). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for multiple myeloma that has returned or not responded, in patients receiving the BCMA CAR T therapy ciltacabtagene autoleucel.
CAR T responses can be strong but are often not durable. The idea: help the cells last. NT-I7, a long-acting form of interleukin-7, a protein that supports T cell growth, is given by injection on days 14 and 35 after the infusion.
The study has two stages. First, dose finding. Later, the expansion is randomized and double blind: some patients receive NT-I7 and others receive a placebo. At Washington University in St. Louis, Michael Slade leads this early safety study.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.